Company news
Biotron Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Executive Director CEO Commences - Appendix 3X
November 8, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
October 27, 2026
Biotron Receives Additional $208,463 Tax Refund
October 22, 2026
Annual Report/Notice of AGM/Proxy Form
October 22, 2026
Director Appointment Michael Thurn & Appendix 3X
October 18, 2026
Appointment of CEO and Executive Director
October 13, 2026
Resignation of Managing Director and Appendix 3Z
September 13, 2026
Change of Share Registry
September 3, 2026
Investor Presentation
September 2, 2026
Appendix 4G
August 26, 2026
Corporate Governance Statement
August 26, 2026
Full Year Statutory Accounts and Appendix 4E
August 26, 2026
Change in substantial holding
August 17, 2026
HBV Treatment to Progress Towards Human Trials
August 16, 2026
Sedarex First Milestone Met
July 12, 2026
$525K R&D Rebate Received
June 3, 2026
Hepatitis B Virus Program Update
March 17, 2026
Half Yearly Report and Accounts
February 26, 2026
Successful Issue of the Entitlement Offer Shortfall
January 29, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 28, 2026
Security Class Reinstatement to Quotation - BITO
December 21, 2025
Rights Issue Close
December 19, 2025
Security Class Suspension from Quotation - BITO
December 14, 2025
Non-Renounceable rights Issue Prospectus
November 18, 2025
Acquisition of Sedarex Limited and $2.5m capital raising
October 15, 2025
Trading Halt
October 12, 2025
Pause in Trading
October 12, 2025
Full Year Statutory Accounts and Appendix 4E
August 27, 2025
Rights Issue Closed
April 7, 2025
Replacement Prospectus
March 12, 2025
Response to ASX Query Letter
March 12, 2025
Supplementary Prospectus
March 4, 2025
Response to ASX Aware Query
March 3, 2025
Prospectus
March 2, 2025
Renounceable Rights Issue
February 27, 2025
Updated Appendix 4C
February 3, 2025
Agreement with C14 Consulting Group
November 26, 2024
$1.8M R&D Rebate Received
October 13, 2024
BIT225-012 Phase 2 COVID-19 clinical trial
September 5, 2024
BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
June 19, 2024
Positive outcomes in BIT225 phase 2 clinical trial in hiv
April 4, 2024
Response to ASX Price Query
March 26, 2024
Completion of Phase 2 COVID clinical trial
August 16, 2023
Second Site Approved for Phase 2 Covid-19 Trial
May 12, 2023
Commencement Phase 2 Covid-19 Clinical Trial
May 3, 2023
Completion of Phase 2 HIV-1 Clinical Trials
March 8, 2023
International Presentation of BIT225 COVID-19 Data
February 20, 2023
$1.43M R&D rebate received
November 18, 2022
Commencement of Rights Trading - BITRC
October 31, 2022
Renounceable Issue
October 26, 2022
Decks
The 5 newest of 101 decks. Every deck is listed under its year.
- Biotech Showcase, Melbourne (September 2026)
Conference · 12 slides · Sep 3, 2026
- Investor Presentation (November 2025)
Investor deck · 32 slides · Nov 11, 2025
- Investor Presentation (October 2025)
Investor deck · 15 slides · Oct 15, 2025
- Shareholder Meeting (November 2024)
Shareholder meeting · 20 slides · Nov 28, 2024
- Shareholder Meeting (November 2024)
Shareholder meeting · 17 slides · Nov 28, 2024